Key Points
- Director William Waddill sold 20,000 PTGX shares on Feb. 6 at an average price of $83.68 for total proceeds of $1,673,600, cutting his position by 71.88% to 7,825 shares.
- Analysts are broadly positive with a consensus "Moderate Buy" rating, an average target of $91.64, and several firms raising targets (as high as $118) and issuing "buy" ratings.
- PTGX opened at $84.49, trades in a 52‑week range of $33.70–$96.54 with a $5.28B market cap, and recently missed quarterly estimates (EPS -$0.62 vs -$0.59 and revenue $4.71M vs $5.41M).
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director William Waddill sold 20,000 shares of the business's stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $654,796. The trade was a 71.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Protagonist Therapeutics Stock Performance
Shares of PTGX opened at $84.49 on Friday. The company has a 50-day simple moving average of $85.65 and a 200-day simple moving average of $73.67. Protagonist Therapeutics, Inc. has a 52 week low of $33.70 and a 52 week high of $96.54. The firm has a market capitalization of $5.28 billion, a P/E ratio of 136.28 and a beta of 2.26.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The firm had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. As a group, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.
Wall Street Analyst Weigh In
PTGX has been the topic of a number of research reports. Citizens Jmp boosted their price objective on Protagonist Therapeutics from $69.00 to $102.00 and gave the company a "market outperform" rating in a research report on Friday, November 7th. Jefferies Financial Group lifted their price target on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a "buy" rating in a research note on Monday, February 2nd. HC Wainwright increased their price objective on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a research note on Friday, January 30th. Truist Financial raised their price objective on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a "buy" rating in a report on Monday, January 5th. Finally, Weiss Ratings upgraded shares of Protagonist Therapeutics from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, December 24th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Protagonist Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $91.64.
Get Our Latest Stock Analysis on Protagonist Therapeutics
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in shares of Protagonist Therapeutics by 30.6% in the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company's stock valued at $482,000 after purchasing an additional 2,334 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company's stock valued at $1,810,000 after purchasing an additional 348 shares during the last quarter. Millennium Management LLC boosted its position in Protagonist Therapeutics by 283.6% in the first quarter. Millennium Management LLC now owns 134,269 shares of the company's stock valued at $6,493,000 after buying an additional 99,269 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Protagonist Therapeutics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company's stock valued at $132,000 after buying an additional 340 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its stake in Protagonist Therapeutics by 19.5% during the second quarter. KLP Kapitalforvaltning AS now owns 10,400 shares of the company's stock worth $575,000 after buying an additional 1,700 shares during the last quarter. 98.63% of the stock is owned by institutional investors.
About Protagonist Therapeutics
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
